Mitotic Index, Microvascular Proliferation, and Necrosis Define 3 Groups of 1p/19q Codeleted Anaplastic Oligodendrogliomas Associated with Different Genomic Alterations

Methods: The histological characteristics of 203 AO patients, enrolled in the French national network POLA, were analyzed. The genomic profiles of 191 cases were studied using genomic arrays. IDH mutational status was assessed by immunohistochemistry and direct sequencing.

Results: 1p/19q codeletion was present in 79% of cases and was associated with alpha-internexin expression (P < 10(-4)), IDH1/2 mutation (P < 10(-4)), chromosome 4 loss (P < 10(-3)), and better overall survival (P < 10(-4)). Based on mitotic index, microvascular proliferation (MVP), and necrosis, 3 groups of 1p/19q codeleted AOs were identified: (group 1) AO with more than 5 mitoses per 10-HPF, no MVP, and no necrosis; (group 2) AO with MVP and no necrosis; and (group 3) AO with MVP and necrosis. Compared with group 1, groups 2 and 3 AOs had a higher mean Ki-67 proliferation index and a higher rate of 9p and 9q losses. Compared with group 2, group 3 AOs had a higher number of chromosomal alterations including chromosome 4 loss. In the subgroup of 157 1p/19q codeleted AOs, chromosomal instability was associated with shorter progression-free survival (P = .024) and shorter overall survival (P = .023).

Conclusions: The present study shows that oligodendrogliomas with classic histological features remain a molecularly heterogeneous entity and should be stratified according to 1p/19q status because of its major prognostic relevance. Moreover, 1p/19q codeleted AOs are also heterogeneous. Interestingly, mitotic index, MVP, and necrosis help to classify them into 3 groups associated with distinct genomic alterations.

Citing Articles

Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.

Himstead A, Chen J, Chu E, Perez-Rosendahl M, Zheng M, Mathew S Biomedicines. 2025; 13(1).

PMID: 39857783 PMC: 11762706. DOI: 10.3390/biomedicines13010201.

Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.

Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A, Appay R Neuro Oncol. 2024; 27(3):755-766.

PMID: 39432559 PMC: 11889709. DOI: 10.1093/neuonc/noae221.

Diffuse leptomeningeal glioneuronal tumor with distinct neuronal and glial components but identical diagnostic molecular and genetic features.

Witten A, Dougherty C, Hao C Neuropathology. 2024; 44(6):440-444.

PMID: 39073721 PMC: 11608919. DOI: 10.1111/neup.12996.

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?.

van den Bent M, French P, Brat D, Tonn J, Touat M, Ellingson B Neuro Oncol. 2024; 26(10):1805-1822.

PMID: 38912846 PMC: 11449017. DOI: 10.1093/neuonc/noae107.

A viral attack on brain tumors: the potential of oncolytic virus therapy.

Mokhtarpour K, Akbarzadehmoallemkolaei M, Rezaei N J Neurovirol. 2024; 30(3):229-250.

PMID: 38806994 DOI: 10.1007/s13365-024-01209-8.

References

Giannini C, Burger P, Berkey B, Cairncross J, Jenkins R, Mehta M . Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008; 18(3):360-9. PMC: 8095535. DOI: 10.1111/j.1750-3639.2008.00129.x. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

Kim J, Park C, Park S, Kim Y, Han J, Kim C . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2010; 82(2):224-7. DOI: 10.1136/jnnp.2009.178806. View

McDonald J, See S, Tremont I, Colman H, Gilbert M, Groves M . The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005; 104(7):1468-77. DOI: 10.1002/cncr.21338. View

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J . IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010; 75(17):1560-6. DOI: 10.1212/WNL.0b013e3181f96282. View

Labussiere M, Idbaih A, Wang X, Marie Y, Boisselier B, Falet C . All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010; 74(23):1886-90. DOI: 10.1212/WNL.0b013e3181e1cf3a. View

Giannini C, Scheithauer B, Weaver A, Burger P, Kros J, Mork S . Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001; 60(3):248-62. DOI: 10.1093/jnen/60.3.248. View

Coulibaly B, Nanni I, Quilichini B, Gaudart J, Metellus P, Fina F . Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. Hum Pathol. 2010; 41(6):815-23. DOI: 10.1016/j.humpath.2009.09.020. View

10.

Jenkinson M, du Plessis D, Smith T, Joyce K, Warnke P, Walker C . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 2006; 129(Pt 7):1884-91. DOI: 10.1093/brain/awl108. View

11.

Griffin C, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart J . Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006; 65(10):988-94. DOI: 10.1097/01.jnen.0000235122.98052.8f. View

12.

Miller C, Dunham C, Scheithauer B, Perry A . Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol. 2006; 24(34):5419-26. DOI: 10.1200/JCO.2006.08.1497. View

13.

Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J . Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002; 161(1):313-9. PMC: 1850690. DOI: 10.1016/S0002-9440(10)64183-1. View

14.

Godfraind C, Rousseau E, Ruchoux M, Scaravilli F, Vikkula M . Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol. 2003; 29(5):462-71. DOI: 10.1046/j.1365-2990.2003.00484.x. View

15.

Craig J, Vena N, Ramkissoon S, Idbaih A, Fouse S, Ozek M . DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881. PMC: 3376148. DOI: 10.1371/journal.pone.0038881. View

16.

Mokhtari K, Ducray F, Kros J, Gorlia T, Idbaih A, Taphoorn M . Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer. 2011; 117(13):3014-26. DOI: 10.1002/cncr.25827. View

17.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

18.

Bigner S, Rasheed B, Wiltshire R, McLendon R . Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol. 2001; 1(1):52-60. PMC: 1919462. DOI: 10.1093/neuonc/1.1.52. View

19.

Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S . SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One. 2012; 7(10):e45950. PMC: 3468603. DOI: 10.1371/journal.pone.0045950. View

20.

Perry A, Aldape K, George D, Burger P . Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004; 101(10):2318-26. DOI: 10.1002/cncr.20625. View